DRD2 and schizophrenia: Here, we describe the biochemical and behavioural characterization of PCC0104005, a novel small-molecule therapeutic agent displaying the combined properties of dopamine D2 receptor antagonism and serotonin transporter binding, which is currently in development for the treatment of schizophrenia.